AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
Press Release
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and …
Yahoo Finance: AnnJi Pharmaceutical Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Kennedy’s Disease Treatment
TAIPEI, March 14, 2023 /PRNewswire/ — AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of …
First-In-Patient Trial of a Drug to Treat Kennedy’s Disease
First-In-Patient Trial of a Drug to Treat Kennedy’s Disease First-In-Patient Trial of a Drug to Treat Kennedy’s Disease AnnJi Pharmaceutical Co., Ltd. has launched a first-in-patient Phase 1/2a study of …
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy’s Disease
AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European …
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA …
AnnJi’s AJ201 Received The National Innovation Award of 2022
On December 3rd,2022, AnnJi received “The National Innovation Award” from the Institute for Biotechnology and Medicine Industry of Taiwan for its new drug development project, AJ201, a Phase 2 stage …
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
